Multidisciplinary Management of Metabolic Dysfunction‐Associated Steatohepatitis: A Single‐Centre European Experience

Metabolic dysfunction‐associated steatotic liver disease (MASLD) can progress to steatohepatitis and fibrosis, often coexisting with obesity, type 2 diabetes, dyslipidaemia and hypertension. We evaluated the effectiveness of a one‐year, Mediterranean, hospital‐based lifestyle programme in patients with fibrotic steatohepatitis. Sixty‐two adults with liver stiffness ≥ F2 were enrolled and followed a personalised Mediterranean diet combined with physical activity counselling, with visits at baseline, 3, 6 and 12 months. Anthropometric, biochemical and clinical parameters were measured. Longitudinal changes were analysed using the Friedman test ( p < 0.05). The mean age was 63.5 years, and 46.8% were women. Comorbidities included hypertension (62.9%), dyslipidaemia (79.0%) and type 2 diabetes (T2D) (45.2%). After 6 and 12 months, significant improvements were observed in weight, body mass index, waist circumference, glycated haemoglobin, liver enzymes and liver stiffness. A coordinated, Mediterranean‐based lifestyle programme led to clinically meaningful improvements in hepatic and cardiometabolic outcomes in patients with fibrotic steatohepatitis.